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OBJECTIVE — The objective of this study was to determine the relationship between A1C
and glycemia in HIV infection.
RESEARCH DESIGN AND METHODS — We completed a prospective cross-sectional
study of 100 HIV-infected adults with type 2 diabetes (77%) or fasting hyperglycemia (23%) with
measured glucose, A1C, mean corpuscular volume (MCV), and fructosamine. A total of 200 HIV-
uninfectedtype2diabeticsubjectsmatchedforkeydemographiccharacteristicsservedascontrolsubjects.
RESULTS — Relativetothecontrolsubjects,A1Cunderestimatedglucoseby294mg/dlin
the HIV-infected subjects. Current nucleoside reverse transcriptase inhibitors (NRTIs), higher
MCV and hemoglobin, and lower HIV RNA and haptoglobin were associated with greater
A1C-glucose discordance. However, only MCV and current NTRI use, in particular abacavir,
remained signiﬁcant predictors in multivariate analyses. Fructosamine more closely reﬂected
glycemia in the HIV-infected subjects.
CONCLUSIONS — A1C underestimates glycemia in HIV-infected patients and is related to
NRTI use. Use of abacavir and increased MCV were key correlates in multivariate analyses.
Fructosamine may be more appropriate in this setting.
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D
iabetes is increasingly recognized in
HIV.Currentguidelinesfortheman-
agement of diabetes in HIV are simi-
lar to diabetes guidelines for the general
population(1).However,apreviouslypub-
lished case series and a retrospective study
noted elevated glucose values relative to
A1C levels in HIV-infected subjects (2,3).
The authors of both the case series and the
retrospectivestudyspeculatedthathemoly-
sis may have contributed to the inaccuracy
of A1C in this setting. Therefore, we sought
to prospectively characterize the relation-
shipbetweenA1Candglucoselevelsinthis
population in relation to hematologic and
metabolic indicators.
RESEARCH DESIGN AND
METHODS— A total of 100 HIV-
infectedadultswithtype2diabetesorhy-
perglycemia (fasting glucose 100 and
126mg/dl)participatedbetweenMarch
2007andMarch2008.Patientswhowere
pregnant or had hemoglobinopathy, re-
centchangesinantiretroviral(ARV)ordi-
abetes therapy, anemia, opportunistic
infection, renal disease, creatinine 1.8
mg/dl, a recent blood transfusion, or cor-
ticosteroid use were excluded. All partic-
ipants gave written informed consent.
Sex-, race-, and age-matched HIV-
uninfected type 2 diabetic control sub-
jects (n  200) were obtained from
MedStar Health’s electronic medical
recordsystem.ExceptforHIVfactors,ex-
clusion criteria were the same. Random
serum glucose and A1C measurements
were obtained. This study was approved
by the National Institute of Allergy and
Infectious Diseases and MedStar institu-
tional review boards.
Measurements included fasting and
nonfastingplasmaandserumglucose,fruc-
tosamine and A1C, and haptoglobin, albu-
min, HIV viral load, and CD4 counts.
Glucose was determined on a Synchron
LX20 (Beckman Coulter, Fullerton, CA),
A1C was determined by ion-exchange
high-performance liquid chromatography
(HPLC) on a Variant Hemoglobin Testing
System (Bio-Rad, Hercules, CA), and fruc-
tosamine was determined by Esoterix labo-
ratory services (Calabasa Hills, CA).
Analyses for control subjects were com-
pleted at MedStar laboratories, and A1C
wasdeterminedbyHPLConaTosohHLC-
723 GHbG7 (Tosoh Bioscience, Rivoli, It-
aly) at Washington Hospital Center. There
is documented good agreement between
Tosoh HLC-723 and Bio-Rad Variant sys-
tems (4–6).
Statistical analysis
Group comparisons were made using
Student’s t tests and 
2 analyses. Random
serum glucose and A1C values in control
subjects were used to generate a reference
regression equation. The following equa-
tion was applied to the measured A1C in
the HIV sample in order to calculate the
predicted glucose.
A1C-glucose discordance 
mean of one fasting and one
random glucose
– predicted glucose for the
measured A1C
Regression analyses were performed to
identify variables associated with A1C-
glucose discordance. Signiﬁcant variables
on univariate analyses were entered into
forward stepwise multivariate regressions.
Current ARV use was coded by drug class;
separate analyses were performed with in-
dividualnucleosidereversetranscriptasein-
hibitors(NRTIs).Allanalyseswererepeated
utilizing the reference equation of A1C and
glucose for the external validation (7).
Fructosamine-glucose discordance
(measured-predicted glucose) was calcu-
latedusingareferenceequation(8).Two-
tailed 0.05 was used for statistical
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means  SEM unless indicated. Data
were analyzed using SAS JMP Version 7.0
(SAS, Cary, NC).
RESULTS— Clinical characteristics of
the HIV-infected and control subjects are
presented in Table 1. For the HIV-
uninfectedcontrolsubjectswithdiabetes,
the following regression equation was
generated:
Glucose (mg/dl)  25.32(A1C)
 43.57 r
2  0.39, P  0.0001
For HIV-infected subjects, the following
equation was generated:
Glucose (mg/dl)  22.56(A1C)
 3.63 r
2  0.46, P  0.0001
Relative to control subjects, A1C under-
estimated glucose by 29  4 mg/dl. Cur-
rent NRTI use (P  0.001), mean
corpuscularvolume(MCV)(P0.0001),
hemoglobin (P  0.04), albumin (P 
0.03), low HIV RNA (P  0.02), and low
haptoglobin (P  0.01) were associated
with A1C-glucose discordance. In multi-
variate analysis, only MCV remained sig-
niﬁcant (P  0.002). When individual
NRTIs were assessed, current abacavir
(P  0.001), lamivudine (P  0.02), and
zidovudine (P  0.03) use were associ-
ated with A1C-glucose discordance. In
multivariate analysis, abacavir use (P 
0.0004) and MCV (P  0.001) were in-
dependent predictors of A1C-glucose
discordance. When A1C-glucose discor-
dance was calculated using a published
referenceequation(7),themajorﬁndings
in this study were unchanged.
For fructosamine, the mean mea-
sured-predicted glucose was 	2.8  5.0
mg/dl. There were no signiﬁcant associa-
tions between fructosamine-glucose dis-
cordance and ARV use, CD4 count, viral
load, or hematologic indexes.
There were inverse correlations be-
tween A1C and MCV (r 	 0.37, P 
0.0002) and haptoglobin and MCV (r 
	0.39, P  0.0001). There was a signif-
icant correlation between haptoglobin
and HIV viral load (r  0.29, P  0.004),
whereas lower haptoglobin was associ-
atedwithNRTIuse(P0.005).Abacavir
use was not associated with MCV or hap-
toglobin levels.
CONCLUSIONS — In this ﬁrst pro-
spective study evaluating the accuracy of
A1C in HIV-infected patients with diabe-
tes, we found that glucose levels were sig-
niﬁcantly higher than anticipated by A1C
levels when compared with HIV-
uninfected control subjects and estab-
lished reference values (7). Use of NRTIs
was strongly associated with this discor-
dance. Fructosamine more accurately
predicted glucose levels and was not af-
fected by use of ARVs.
Though earlier reports suggested that
hemolysis played a role in the described
discordance (2,3), neither study directly
evaluated haptoglobin relative to A1C-
glucosediscordance.Inthisstudy,hapto-
globin was not an independent predictor
of A1C-glucose discordance. Thus, he-
molysis seems an unlikely cause.
Macrocytosis is a well-documented
effect of the thymidine analogs (9,10). In-
creased MCV, driven largely by use of
NRTIs, is an important factor in the rela-
tionship between A1C and glycemia.
Prior investigation shows that MCV de-
creases in parallel to increases in A1C and
correlates with cell age (11,12). Similarly,
we identiﬁed a strong relationship be-
tween A1C and MCV.
Additionally, we found that abacavir
was associated with A1C-glucose discor-
dance. Abacavir is not regarded as hemo-
toxic (13), and there was no relationship
between abacavir and macrocytosis. In
multivariate analyses, abacavir use re-
mained a predictor of A1C-glucose dis-
cordance independent of MCV and
cumulativeexposuretootherNRTIs.Fur-
ther investigation is needed to evaluate
potential mechanisms underlying these
observations.
Fructosamine reliably predicted glu-
coseinourcohortandwasnotinﬂuenced
by MCV or current abacavir or NRTI use.
Table 1—Demographic and clinical characteristics of study participants
HIV-infected Control P
n 100 200
Age (years) 52  15 2  1 0.6
Sex (% male/female) 70/30 70/30 0.9
Race/ethnicity (%) 0.1
African American 65 65.5
Caucasian 25 27.5
Hispanic 7 7
Asian/other 3 0
Duration of HIV (years) 13.5  0.7 —
CD4 (cells/ml) 561  25 —
HIV viral load 50 copies/ml (%) 61 —
Current ARV therapy (%) 78 —
NRTI 78 —
Protease inhibitor 42 —
Non-NRTI 38 —
Type 2 diabetes (%) 77 100
Diabetes duration (years) 6.8  0.6 —
Current insulin use (%) 30 29 0.9
BMI (kg/m
2) 30.6  0.8 35.2  0.6 0.0001
A1C (%)* 6.7  0.2 8.1  0.1 0.0001
Mean plasma glucose (mg/dl) 156  5—
Serum glucose (mg/dl)* 176  7 161  6 0.09
Mean fructosamine (
mol/l) 275  6—
Hemoglobin (g/dl) 13.9  0.1 —
MCV (fL) 96  1—
Haptoglobin (mg/dl) 111  8—
Albumin (g/dl) 3.8  0.05 —
A1C-glucose discordance (mg/dl) 29  4—
Current NRTI
Yes (n  78) 35  5† —
No (n  22) 6  5† —
Current abacavir
Yes (n  24) 56  11† —
No (n  76) 20  3† —
Data are means  SEM. *Nonfasting values only. †Difference between current use (yes vs. no) signiﬁcantly
different at P  0.0001 for NRTI and P  0.003 for abacavir.
A1C underestimates glycemia in HIV infection
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stitute for A1C in the setting of HIV and
macrocytosis.
One limitation is that we did not ob-
tain multiple glucose determinations but
rather one fasting and one random deter-
mination. We believe this is mitigated by
the large number of patients in our co-
hort. We used contemporary HIV-
uninfected control subjects matched on
key demographic characteristics. We
were also able to replicate all of our key
ﬁndings using an established reference
equation (7).
Our study suggests that A1C may not
be accurate for assessing glycemia among
HIV-infected patients on NRTI-based
therapy, especially those with macrocyto-
sis or those on abacavir. Fructosamine
may be an appropriate alternative for as-
sessment of glycemia in this context.
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